Investment Thesis
Apimeds is in critical financial distress as a pre-revenue pharmaceutical company with $35.1M net losses, $12.2M operating losses, and only $979.5K in cash against $2.1M annual burn rate. Current ratio of 0.90x combined with negative operating cash flow creates severe liquidity risk with approximately 5 months of runway, indicating potential insolvency without immediate financing or revenue generation.
Strengths
- Low leverage with 0.00x debt-to-equity ratio and only $14.7M in liabilities
- Substantial asset base of $141.2M provides some balance sheet cushion
- Clean capital structure without significant long-term debt burden
Risks
- Zero revenue indicates failed commercialization or pre-clinical stage with no viable product pipeline generating sales
- Critical liquidity crisis with current ratio of 0.90x and cash position of only $979.5K creating imminent solvency concerns
- Accelerating losses with net income deteriorating 331.7% year-over-year while burning $2.1M in operating cash monthly
- Estimated cash runway of approximately 5 months at current burn rate with no positive free cash flow generation
- Absence of insider purchases in past 90 days suggests management lacks confidence in company viability
- Pre-revenue pharmaceutical company facing typical development risks with deteriorating financial position
Key Metrics to Watch
- Cash position and monthly burn rate (immediate solvency indicator)
- Revenue generation and path to commercialization (essential for survival)
- Operating cash flow trajectory and timeline to cash flow breakeven
- Debt covenant compliance and refinancing needs or bankruptcy risk
- Pipeline progress and clinical trial results for drug candidates
Financial Metrics
Revenue
N/A
Net Income
-35.1M
EPS (Diluted)
$-2.26
Free Cash Flow
-2.1M
Total Assets
141.2M
Cash
979.5K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-27.7%
ROA
-24.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.90x
Quick Ratio
0.90x
Debt/Equity
0.00x
Debt/Assets
10.4%
Interest Coverage
-1,452.93x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-27T07:20:01.347609 |
Data as of: 2026-03-31 |
Powered by Claude AI